Abstract
DNA methylation is one of the best-known epigenetic modifications in mammals. The alteration of DNA methylation patterns has been found to be related to many diseases, including cancer. It is well-known that during carcinogenesis, a sitespecific DNA hypermethylation and a global DNA hypomethylation take place. This overall loss of DNA methylation has been proposed as a valid biomarker for cancer. Given its medical utility, in recent years it has become apparent that there is a need to develop methods for the analysis of DNA methylation using different approaches: global, locus-specific, or genome-wide. Here we review some of these techniques and discuss their potential clinical utility. © 2012 by Walter de Gruyter. Berlin. Boston.
Author supplied keywords
Cite
CITATION STYLE
Toraño, E. G., Petrus, S., Fernandez, A. F., & Fraga, M. F. (2012, October 1). Global DNA hypomethylation in cancer: Review of validated methods and clinical significance. Clinical Chemistry and Laboratory Medicine. https://doi.org/10.1515/cclm-2011-0902
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.